Medivation Reports First Quarter 2016 Financial Results

Needham & Company Sees Little Upside in Medivation (MDVN)

Needham & Company analyst Chad Messer weighed in on Hold-rated Medivation (NASDAQ: MDVN), saying another Xtandi miss is being overlooked by the takeover battle. The analyst sees little upside from current levels.

Messer commented, "Medivation rejected Sanofi's recent $52.50/share ($9.3 billion) takeover bid. However,... More

Medivation (MDVN) PT Raised to $56 at Jefferies

Jefferies analyst Biren Amin bumped his price target on Medivation (NASDAQ: MDVN) to $56.00 (from $52.00) but maintained a Hold rating.

Amin commented, "MDVN reported $307.6M in U.S. Xtandi sales despite seasonal headwinds and reiterated sales guidance of $1.425-1.525B in 2016 and issued long term... More

Citi Upgrades Medivation (MDVN) to Buy

Citi upgraded Medivation (NASDAQ: MDVN) from Neutral to Buy.

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $59.22 yesterday.

Medivation (MDVN) PT Raised to $70 at RBC Capital

RBC Capital analyst Simos Simeonidis lifted his price target on Medivation (NASDAQ: MDVN) to $70.00 (from $40.00) while maintaining a Sector Perform rating on the stock.

Simeonidis commented, "MDVN reported $548M in WW Xtandi sales, flat Q/Q, but reiterated 2016 guidance on... More

Medivation (MDVN) Misses Q1 EPS by 12c, Sales Miss; Reaffirms

Medivation (NASDAQ: MDVN) reported Q1 EPS of $0.11, $0.12 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $182.5 million versus the consensus estimate of $196.61 million.

"Medivation is off to a strong start in 2016 as we continue to expand our leadership position in oncology, extend XTANDI's reach into urology and other areas, and advance our robust late-stage pipeline," said David Hung, M.D., Founder, President and Chief Executive Officer of Medivation. "The... More